巴伐利亚诺德公司捐赠 75,000 剂 MVA-BN 疫苗，并将向新建立的全球猴痘疫苗应急储备库供应 150,000 剂。
Bavarian Nordic donates 75,000 doses of MVA-BN and will also supply 150,000 doses to new global mpox vaccine emergency stockpile.
建立应急储备是全球猴痘防备工作的重要里程碑，有助于确保及时、公平地获得疫苗。
Building emergency reserves is an important milestone in global mpox preparedness, helping ensure timely and equitable access to vaccines.
这一新举措体现了巴伐利亚诺德公司作为全球卫生安全可信赖合作伙伴的长期角色，以及其通过疫苗保护人群和社区、挽救生命的使命。
This new initiative reflects Bavarian Nordic's longstanding role as a trusted partner in global health security and its mission to protect people and communities, and save lives, through vaccines.
丹麦哥本哈根，2026 年 10 月 27 日 — 巴伐利亚诺德公司（OMX: BAVA）今日宣布，将通过向新建立的全球猴痘疫苗应急储备库捐赠 75,000 剂 MVA-BN 疫苗，加强全球对猴痘的防备，帮助确保在需要的时间和地点提供防护。新储备库的建立标志着全球猴痘防备工作的重要里程碑，有助于确保及时、公平地获得疫苗，并使世界各地社区能够有效应对疫情爆发。
COPENHAGEN, Denmark, October 27, 2026 - Bavarian Nordic A/S (OMX: BAVA) today announced that it will strengthen global preparedness for mpox through a donation of 75,000 doses of its MVA-BN vaccine to the newly established global mpox vaccine emergency stockpile, helping ensure that protection is available when and where it is needed. The creation of a new stockpile marks an important milestone in global mpox preparedness, helping to ensure timely and equitable access to vaccines and enabling effective outbreak response for communities around the world.
该储备库由疫苗供应国际协调小组（ICG）管理，该机制由世界卫生组织（WHO）主办，负责协调向应对疫情的国家分配和部署应急疫苗供应。储备库的初始资金由全球疫苗免疫联盟（Gavi）提供。
It is managed by the International Coordinating Group (ICG) on Vaccine Provision, a mechanism hosted by WHO that coordinates the allocation and deployment of emergency vaccine supplies to countries responding to outbreaks. Initial funding for the stockpile has been provided by Gavi, the Vaccine Alliance.
此次捐赠是对新授予的向储备库供应 150,000 剂疫苗合同的补充。巴伐利亚诺德公司通过疫苗供应和捐赠作出的贡献，体现了其对全球卫生安全的长期承诺，以及其通过疫苗保护人群和社区、挽救生命的使命。
The donation complements a newly awarded contract to supply 150,000 doses to the stockpile. Bavarian Nordic's contribution through both vaccine supply and donation reflects its longstanding commitment to global health security and its mission to protect people and communities, and save lives, through vaccines.
巴伐利亚诺德公司公共防备高级副总裁 Hitesh Sahni 表示：“传染病不分国界，当疫情爆发时，社区需要及时获得防护。建立全球猴痘疫苗应急储备库是加强未来疫情防备的重要里程碑。确保及时、公平地获得疫苗对于保护人群和实现有效的公共卫生应对至关重要。我们很荣幸能与 ICG 合作伙伴开启新的合作，共同构建更加协调、更有韧性的应对机制，以应对猴痘这一反复出现的威胁。”
Hitesh Sahni, Senior Vice President, Public Preparedness at Bavarian Nordic, said: "Infectious diseases do not stop at borders, and communities need timely access to protection when outbreaks occur. The establishment of a global mpox vaccine emergency stockpile is an important milestone in strengthening preparedness for future outbreaks. Ensuring timely and equitable access to vaccines is critical to protecting populations and enabling an effective public health response.
关于天花/猴痘疫苗 MVA-BN（即改良安卡拉株-巴伐利亚诺德疫苗），是美国、瑞士、新加坡和墨西哥（商品名 JYNNEOS）、加拿大（商品名 IMVAMUNE）以及欧盟/欧洲经济区和英国（商品名 IMVANEX）唯一获批的非复制型猴痘疫苗。该疫苗最初是作为天花疫苗与美国政府合作开发的，旨在确保美国民众（包括不建议接种复制型天花疫苗的免疫受损人群）的天花疫苗供应。目前 MVA-BN 适用于被认为有天花或猴痘感染风险的个体。
We are proud to embark on a new collaboration with ICG partners to build a more coordinated and resilient response to the recurring threat of mpox." About the smallpox/mpox vaccine MVA-BN, or Modified Vaccinia Ankara-Bavarian Nordic, is the only non-replicating mpox vaccine approved in the U.S., Switzerland, Singapore and Mexico (marketed as JYNNEOS), Canada (marketed as IMVAMUNE), and the EU/EAA and United Kingdom (marketed as IMVANEX). It was originally developed as a smallpox vaccine in collaboration with the U.S. government to ensure the supply of a smallpox vaccine for the US population, including immunocompromised individuals who are not recommended vaccination with replicating smallpox vaccines. MVA-BN is now indicated for use for individuals considered at risk for smallpox or mpox infection.
巴伐利亚诺德公司一直是国家储备库的长期疫苗供应商。在 2022-2024 年猴痘疫情期间，该公司通过向全球 70 多个国家扩大疫苗供应，支持了各国政府和国际组织。
Bavarian Nordic has been a long-term supplier of the vaccine to national stockpiles. During the 2022-2024 mpox outbreaks, the Company supported governments and international organizations by expanding access to the vaccine to more than 70 countries worldwide.
2024年，MVA-BN获得世界卫生组织（WHO）预认证，可用于12岁及以上人群，使得联合国专注于儿童健康的机构能够采购该疫苗。最近，欧盟委员会批准在欧盟/欧洲经济区（EEA）延长该疫苗的上市许可，纳入2岁至12岁以下儿童。这一扩展适应症进一步有助于满足感染风险较高的年轻人群对猴痘疫苗的未被满足需求。
In 2024, MVA-BN received WHO prequalification for the use of the vaccine by individuals aged 12 years and older, enabling procurement through the UN agency focusing on children's health. More recently, the European Commission approved an extension of the vaccine's marketing authorization in the EU/EEA to include children aged 2 to under 12 years. This expanded indication further helps to address the unmet need for mpox vaccines among younger populations at increased risk of infection.
巴伐利亚诺德公司（Bavarian Nordic）正与全球合作伙伴开展额外临床研究，以进一步扩大MVA-BN在其他弱势人群中的可及性。同时，公司正在开发新的制造工艺，以实现产能扩大，满足未来增长的需求。关于巴伐利亚诺德公司巴伐利亚诺德公司是一家全球疫苗企业，使命是通过创新疫苗改善健康、挽救生命。我们是政府采购猴痘和天花疫苗的首选供应商，以加强公共卫生应对准备，并提供领先的旅行疫苗组合。
Bavarian Nordic is working with global partners on additional clinical studies to further expand the availability of MVA-BN for other vulnerable populations. In parallel, the Company is developing new manufacturing processes to allow for scaling of capacity to meet increased demand in the future. About Bavarian Nordic Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and offer a leading portfolio of travel vaccines.
更多信息请访问www.前瞻性声明本公告包含前瞻性声明，涉及风险、不确定性及其他因素，其中许多超出我们控制范围，可能导致实际结果与前瞻性声明中讨论的结果存在重大差异。前瞻性声明包括关于我们的计划、目标、宗旨、未来事件、业绩及/或其他非历史信息的陈述。所有此类前瞻性声明均受上述警示声明及可能随前瞻性声明附带的任何其他警示声明的明确限制。
For more information, visit www. Forward-looking statements This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements.
除法律要求外，我们无义务公开更新或修订前瞻性声明，以反映声明发布日期后的后续事件或情况。投资者联系人：投资者关系负责人：Anders Hjort，ahjo@bavarian-nordic.com，电话：+45 44 74 99 58 Graham Morrell，Gilmartin Group，graham@gilmartinir.com，电话：+1 781 686 9600媒体联系人：Isabel Hagbrink，媒体关系负责人，isha@bavarian-nordic.com，电话：+45 71 79 67 33附件：巴伐利亚北欧公司将为全球猴痘应急储备库供应并捐赠疫苗
We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law. Contact investors: Anders Hjort, Head of Investor Relations, ahjo@bavarian-nordic.com, Tel: +45 44 74 99 58 Graham Morrell, Gilmartin Group, graham@gilmartinir.com, Tel: +1 781 686 9600 Contact media: Isabel Hagbrink, Head of Media Relations, isha@bavarian-nordic.com, Tel: +45 71 79 67 33 Attachment Bavarian Nordic to Supply and Donate Vaccines for Global Mpox Emergency Stockpile